Michael J. Overman

31.1k citations

447 papers · 16.5k indexed · 5 hit papers · h-index 58

Impact in

Oncology top 0.05%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis

Papers in

Oncology 322
- Colorectal Cancer Treatments and Studies 200
- Cancer Immunotherapy and Biomarkers 76
- Pancreatic and Hepatic Oncology Research 59
Cancer Research 122
- Cancer Genomics and Diagnostics 107

Co-authors: Scott Kopetz Cathy Eng Robert A. Wolff Sara Lonardi Thierry André Heinz‐Josef Lenz Ray McDermott Andrew Hill
Journals: Journal of Clinical Oncology (191 papers)Annals of Oncology (27 papers)Clinical Colorectal Cancer (13 papers)Clinical Cancer Research (12 papers)The Oncologist (12 papers)
Partner nations: United States Italy France

In The Last Decade

Michael J. Overman

426 papers receiving 16.3k citations

Hit Papers

5 papers align trajectories log scale

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 2022 · 154 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Annals of Oncology
2019 JAMA Oncology
2018 Journal of Clinical Oncology
2017 The Lancet Oncology
2009 Journal of Clinical Oncology

Peers

Countries citing papers authored by Michael J. Overman

Since Specialization

Citations

This map shows the geographic impact of Michael J. Overman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Overman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Overman more than expected).

Fields of papers citing papers by Michael J. Overman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Overman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Overman. The network helps show where Michael J. Overman may publish in the future.

Co-authors

The 25 scholars most cited alongside Michael J. Overman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael J. Overman Line = papers co-authored together Michael J. Overman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	1531TiP TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC Annals of Oncology ·Michael J. Overman, R. Laeufle, Iran de Maria Leitão NUNES, Jean‐François Henry, حسني بليل, J Woyke, S. Kim, Heng Zou	2024	1
2	1631P Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC) Annals of Oncology ·Zaid Memon, J. Salan, N. A. Tsalikova, Matthew H. G. Katz, Naruhiko Ikoma, 芳夫滝沢, Michael J. Overman, Shubham Pant, Christine Y. Wang, Robert A. Wolff, Milind Javle, Cullen M. Taniguchi, Ethan B. Ludmir, Prajnan Das, Albert C. Koong, Omar I. Vivar, S. Liu, Eric P. Tamm, Manoop S. Bhutani, Eugene J. Koay	2023	2
3	631P Using the unique somatic mutation profile of POLE loss of proof-reading mutation helps in selection of patients who may benefit from immunotherapy Annals of Oncology ·Giovanni Maddalena, M.-C. Seghaye, Zhou Shujia, Aldeb Perera, Abdelrahman Yousef, Michael J. Overman, Scott Kopetz, John Paul Shen	2023	1
4	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer Journal for ImmunoTherapy of Cancer ·M. Rashid, Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, María Elena Elez, Marwan Fakih, Priya Jayachandran, M. Kuballa, Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Chiara Cremolini, Javier Ros, Margherita Ambrosini, Christopher O'hara, Rossana Intini, Michael J. Overman, Rosalba Miceli, Filippo Pietrantonio	2023	13
5	Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience The Oncologist ·Ida Yati, Jane E. Rogers, Hyunsoo Hwang, Wei Qiao, Lianchun Xiao, Arvind Dasari, Arya Samodra Hening, Van K. Morris, Robert A. Wolff, Kanwal Raghav, Ryan Huey, Christine M. Parseghian, Jason Willis, Scott Kopetz, Michael J. Overman, Benny Johnson	2022	14
6	Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors. Journal of Clinical Oncology ·Kaysia Ludford, Kanwal Raghav, Mariela A. Blum Murphy, Nicole D. Fleming, Douglas A. Nelson, Michael Sangmin Lee, Brandon G. Smaglo, Y. Nancy You, Clara Ramírez González, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, P.J. Myers, Arvind Dasari, Jane V. Thomas, Wai Chin Foo, Wei Qiao, Scott Kopetz, Michael J. Overman	2021	8
7	Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary Clinical Cancer Research ·Kanwal Raghav, Hyunsoo Hwang, Alexandre A. Jácome, Balachandran Vishnu, Rosanna O'Keeffe, Ryan Huey, Melek BÜYÜKEREN, 尚登土屋, Brandon G. Smaglo, Aurelio Matamoros, Jeannelyn S. Estrella, T. V. Solomeina, Michael J. Overman, Xuemei Wang, F. Anthony Greco, Jonathan M. Loree, Gauri R. Varadhachary	2021	26
8	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer Clinical Cancer Research ·Amir Mehrvarz Sarshekeh, TT Koca, Jason Roszik, Ganiraju C. Manyam, Shailesh Advani, Riham Katkhuda, Anuj Verma, Michael Lam, Jason Willis, John Paul Shen, Jeffrey S. Morris, Jennifer S. Davis, Jonathan M. Loree, B Liberman, Jaffer A. Ajani, Dipen M. Maru, Michael J. Overman, Scott Kopetz	2021	40
9	Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies JNCI Cancer Spectrum ·Joseph M. Unger, Dawn L. Hershman, Raymond U. Osarogiagbon, Anirudh Gothwal, Seerat Anand, Arvind Dasari, Michael J. Overman, Jonathan M. Loree, Kanwal Raghav	2020	75
10	Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial Journal of Pain and Symptom Management ·David Hui, Marie Jurecki-Tiller, Штыков Дмитрий Романович, Diane Liu, 邹新茂, Ahmed O. Kaseb, Milind Javle, Michael J. Overman, Sriram Yennurajalingam, Colleen M. Gallagher, Éduardo Bruera	2020	1
11	Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Journal of Clinical Oncology ·Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong, Heinz‐Josef Lenz, Fabio Gelsomino, Massimo Aglietta, Michael A. Morse, Eric Van Cutsem, Ray McDermott, Andrew Hill, Michael B. Sawyer, Alain Hendlisz, Bart Neyns, Magali Svrcek, Rebecca A. Moss, Jean-Marie Ledeine, Z. Alexander Cao, Shital Kamble, Scott Kopetz, Thierry André Hit paper breakdown →	2018	1429
12	Underreporting of Research Biopsies from Clinical Trials in Oncology Clinical Cancer Research ·Christine M. Parseghian, Kanwal Raghav, Robert A. Wolff, Joe Ensor, James C. Yao, Lee M. Ellis, Alda L. Tam, Michael J. Overman	2017	14
13	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer Clinical Cancer Research ·Christine M. Parseghian, Nila U. Parikh, Ji Yuan Wu, Zhi-Qin Jiang, Laura E. Henderson, Feng Tian, Brice Pastor, Marc Ychou, Kanwal Raghav, Arvind Dasari, David R. Fogelman, Αναστασία Κατσιαμπούρα, David G. Menter, Robert A. Wolff, Cathy Eng, Michael J. Overman, Alain R. Thierry, Gary E. Gallick, Scott Kopetz	2017	47
14	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes Clinical Cancer Research ·Jonathan M. Loree, Allan Andresson Lima Pereira, Michael Lam, Alexandra N. Willauer, Kanwal Raghav, Arvind Dasari, Van K. Morris, Shailesh Advani, David G. Menter, Cathy Eng, Kenna Shaw, Russell R. Broaddus, Mark J. Routbort, Yusha Liu, Jeffrey S. Morris, Rajyalakshmi Luthra, Funda Meric‐Bernstam, Michael J. Overman, Dipen M. Maru, Scott Kopetz	2017	201
15	Modeling of Patient-Derived Xenografts in Colorectal Cancer Molecular Cancer Therapeutics ·Αναστασία Κατσιαμπούρα, Kanwal Raghav, Zhi-Qin Jiang, David G. Menter, Andreas Varkaris, Maria Pia Morelli, Mikael Melbye, Ji Yuan Wu, Alexey V. Sorokin, Bahar Salimian Rizi, Christopher A. Bristow, Feng Tian, Susan Airhart, Mingshan Cheng, Bradley M. Broom, Jeffrey S. Morris, Michael J. Overman, Garth Powis, Scott Kopetz	2017	38
16	Circulating DNA Demonstrates Convergent Evolution and Common Resistance Mechanisms during Treatment of Colorectal Cancer Clinical Cancer Research ·Alain R. Thierry, Brice Pastor, Zhi-Qin Jiang, Αναστασία Κατσιαμπούρα, Christine M. Parseghian, Jonathan M. Loree, Michael J. Overman, Cynthia Sánchez, Safia El Messaoudi, Marc Ychou, Scott Kopetz	2017	60
17	A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients Supportive Care in Cancer ·David R. Fogelman, Jeffrey S. Morris, Lianchun Xiao, Moustapha Hassan, Carlo Smuraglia, Michael J. Overman, Masoud Haasan, Rachna T. Shroff, Gauri R. Varadhachary, Robert A. Wolff, Luis M. Vence, Anirban Maitra, Charles S. Cleeland, E. BUNCEL	2017	24
18	Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression Clinical Cancer Research ·Arun Satelli, Abhisek Mitra, Zachary Brownlee, Xueqing Xia, Seth Bellister, Michael J. Overman, Scott Kopetz, Lee M. Ellis, Qing H. Meng, Shulin Li	2014	190
19	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations Molecular Cancer Therapeutics ·Prasanth Ganesan, Filip Jankú, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha‐Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, Scott Kopetz, Robert A. Wolff, Razelle Kurzrock	2013	38
20	High Survival Rate After Two-Stage Resection of Advanced Colorectal Liver Metastases: Response-Based Selection and Complete Resection Define Outcome Journal of Clinical Oncology ·Antoine Brouquet, Eddie K. Abdalla, Scott Kopetz, Christopher R. Garrett, Michael J. Overman, Cathy Eng, Andréas Andreou, Evelyne M. Loyer, David C. Madoff, Steven A. Curley, Jean‐Nicolas Vauthey	2011	272

About Michael J. Overman

Michael J. Overman is a scholar working on Oncology, Cancer Research, Pathology and Forensic Medicine, Gastroenterology and Pulmonary and Respiratory Medicine, having authored 447 papers that have together received 16.5k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (200 papers), Genetic factors in colorectal cancer (132 papers), Cancer Genomics and Diagnostics (107 papers), Cancer Immunotherapy and Biomarkers (76 papers), Gastric Cancer Management and Outcomes (60 papers), Pancreatic and Hepatic Oncology Research (59 papers), Gastrointestinal Tumor Research and Treatment (38 papers) and Intraperitoneal and Appendiceal Malignancies (36 papers). The work is most often cited by research in Oncology (11.2k citations), Hepatology (2.3k citations), Pathology and Forensic Medicine (4.1k citations), Cancer Research (3.1k citations) and Gastroenterology (1.1k citations). Michael J. Overman has collaborated with scholars based in United States, Italy and France. Frequent co-authors include Scott Kopetz, Cathy Eng, Robert A. Wolff, Sara Lonardi, Thierry André, Heinz‐Josef Lenz, Ray McDermott, Andrew Hill, Jean‐Nicolas Vauthey and Rebecca A. Moss. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Clinical Colorectal Cancer, Clinical Cancer Research and The Oncologist.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact